Vapaliximab
Vapaliximab is a chimeric monoclonal antibody[1] and an experimental immunosuppressive drug. Development was discontinued by 2012.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | VAP-1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
 N Y (what is this?) (verify) | |
References
- WHO Drug Information
- "Vapaliximab - AdisInsight". adisinsight.springer.com. Retrieved 2 January 2019.
| Intracellular (initiation) |
| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.